Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
12,214
archived clinical trials in
Women's Studies

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Status: Enrolling
Updated:  12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Status: Enrolling
Updated: 12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Status: Enrolling
Updated:  12/31/1969
Duke University
mi
from
Durham, NC
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Status: Enrolling
Updated: 12/31/1969
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Status: Enrolling
Updated:  12/31/1969
Case Western Reserve Univ
mi
from
Cleveland, OH
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Status: Enrolling
Updated: 12/31/1969
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Status: Enrolling
Updated:  12/31/1969
Ohio State University
mi
from
Columbus, OH
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Status: Enrolling
Updated: 12/31/1969
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh-Magee Womens Hospital
mi
from
Pittsburgh, PA
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh-Magee Womens Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Status: Enrolling
Updated:  12/31/1969
Brown University
mi
from
Providence, RI
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Status: Enrolling
Updated: 12/31/1969
Brown University
mi
from
Providence, RI
Click here to add this to my saved trials
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Status: Enrolling
Updated:  12/31/1969
University of Texas - Southwest
mi
from
Dallas, TX
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Status: Enrolling
Updated: 12/31/1969
University of Texas - Southwest
mi
from
Dallas, TX
Click here to add this to my saved trials
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Status: Enrolling
Updated:  12/31/1969
Univ of Texas Galveston
mi
from
Galveston, TX
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Status: Enrolling
Updated: 12/31/1969
Univ of Texas Galveston
mi
from
Galveston, TX
Click here to add this to my saved trials
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Status: Enrolling
Updated:  12/31/1969
University of Utah Medical Center
mi
from
Salt Lake City, UT
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Status: Enrolling
Updated: 12/31/1969
University of Utah Medical Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Status: Enrolling
Updated:  12/31/1969
The University of Texas, Houston
mi
from
Houston, TX
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Status: Enrolling
Updated: 12/31/1969
The University of Texas, Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers
A Pharmacokinetic/Pharmacodynamic Study With a Phase I Run-In With a PARP Inhibitor (Olaparib) in Combination With Carboplatin for Refractory or Recurrent Women's Cancers
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers
A Pharmacokinetic/Pharmacodynamic Study With a Phase I Run-In With a PARP Inhibitor (Olaparib) in Combination With Carboplatin for Refractory or Recurrent Women's Cancers
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase I Trial of Cytarabine and Lenalidomide in Relapsed or Refractory Acute Myeloid Leukemia Patients
Status: Enrolling
Updated:  12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase I Trial of Cytarabine and Lenalidomide in Relapsed or Refractory Acute Myeloid Leukemia Patients
Status: Enrolling
Updated: 12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Influenza and Text Messaging in Pregnancy
Text Messaging For Preventative Health During Pregnancy; Improving Influenza Vaccination Rates In Pregnancy: A Randomized Controlled Trial of Text Messaging to Increase Vaccine Uptake
Status: Enrolling
Updated:  12/31/1969
Magee-Womens Hospital of UPMC
mi
from
Pittsburgh, PA
Influenza and Text Messaging in Pregnancy
Text Messaging For Preventative Health During Pregnancy; Improving Influenza Vaccination Rates In Pregnancy: A Randomized Controlled Trial of Text Messaging to Increase Vaccine Uptake
Status: Enrolling
Updated: 12/31/1969
Magee-Womens Hospital of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
FaceBase Biorepository
FaceBase Biorepository
Status: Enrolling
Updated:  12/31/1969
University of Iowa
mi
from
Iowa City, IA
FaceBase Biorepository
FaceBase Biorepository
Status: Enrolling
Updated: 12/31/1969
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
A Phase II Study of Optimally Dosed Clofarabine in Combination With Low-Dose TBI to Decrease Relapse Rates After Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients With AML
Status: Enrolling
Updated:  12/31/1969
Ochsner Medical Center Jefferson
mi
from
New Orleans, LA
Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
A Phase II Study of Optimally Dosed Clofarabine in Combination With Low-Dose TBI to Decrease Relapse Rates After Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients With AML
Status: Enrolling
Updated: 12/31/1969
Ochsner Medical Center Jefferson
mi
from
New Orleans, LA
Click here to add this to my saved trials
Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
A Phase II Study of Optimally Dosed Clofarabine in Combination With Low-Dose TBI to Decrease Relapse Rates After Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients With AML
Status: Enrolling
Updated:  12/31/1969
VA Puget Sound Health Care System
mi
from
Seattle, WA
Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
A Phase II Study of Optimally Dosed Clofarabine in Combination With Low-Dose TBI to Decrease Relapse Rates After Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients With AML
Status: Enrolling
Updated: 12/31/1969
VA Puget Sound Health Care System
mi
from
Seattle, WA
Click here to add this to my saved trials
Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
A Phase II Study of Optimally Dosed Clofarabine in Combination With Low-Dose TBI to Decrease Relapse Rates After Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients With AML
Status: Enrolling
Updated:  12/31/1969
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
A Phase II Study of Optimally Dosed Clofarabine in Combination With Low-Dose TBI to Decrease Relapse Rates After Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients With AML
Status: Enrolling
Updated: 12/31/1969
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
A Phase II Study of Optimally Dosed Clofarabine in Combination With Low-Dose TBI to Decrease Relapse Rates After Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients With AML
Status: Enrolling
Updated:  12/31/1969
University of Colorado Hospital
mi
from
Aurora, CO
Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
A Phase II Study of Optimally Dosed Clofarabine in Combination With Low-Dose TBI to Decrease Relapse Rates After Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients With AML
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Clearwater, FL
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Clearwater, FL
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Miami, FL
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
West Palm Beach, FL
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Honolulu, HI
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Honolulu, HI
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Iowa City, IA
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Iowa City, IA
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Wichita, KA
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Wichita, KA
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Bardstown, KY
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Bardstown, KY
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Omaha, NE
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Omaha, NE
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Albuquerque, NM
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
New York, NY
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Chapel Hill, NC
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
New Bern, NC
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
New Bern, NC
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Tulsa, OK
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Tulsa, OK
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Portland, OR
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Carnegie, PA
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Carnegie, PA
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Erie, PA
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Erie, PA
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Erie, PA
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Erie, PA
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Philadelphia, PA
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Pleasant Hills, PA
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Pleasant Hills, PA
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Wenatchee, WA
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Wenatchee, WA
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Westmead,
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Westmead,
Click here to add this to my saved trials
Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)
17-alpha-Hydroxyprogesterone Caproate (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM), Double-blinded Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
University of South Alabama Medical Center
mi
from
Mobile, AL
Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)
17-alpha-Hydroxyprogesterone Caproate (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM), Double-blinded Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
University of South Alabama Medical Center
mi
from
Mobile, AL
Click here to add this to my saved trials
Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)
17-alpha-Hydroxyprogesterone Caproate (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM), Double-blinded Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Desert Good Samaritan Hospital
mi
from
Mesa, AZ
Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)
17-alpha-Hydroxyprogesterone Caproate (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM), Double-blinded Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Desert Good Samaritan Hospital
mi
from
Mesa, AZ
Click here to add this to my saved trials
Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)
17-alpha-Hydroxyprogesterone Caproate (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM), Double-blinded Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Banner Good Samaritan Hospital
mi
from
Phoenix, AZ
Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)
17-alpha-Hydroxyprogesterone Caproate (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM), Double-blinded Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Banner Good Samaritan Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)
17-alpha-Hydroxyprogesterone Caproate (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM), Double-blinded Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Tucson Medical Center
mi
from
Tucson, AZ
Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)
17-alpha-Hydroxyprogesterone Caproate (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM), Double-blinded Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Tucson Medical Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)
17-alpha-Hydroxyprogesterone Caproate (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM), Double-blinded Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Long Beach Memorial Medical Center
mi
from
Long Beach, CA
Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)
17-alpha-Hydroxyprogesterone Caproate (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM), Double-blinded Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Long Beach Memorial Medical Center
mi
from
Long Beach, CA
Click here to add this to my saved trials
Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)
17-alpha-Hydroxyprogesterone Caproate (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM), Double-blinded Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Good Samaritan Hospital
mi
from
San Jose, CA
Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)
17-alpha-Hydroxyprogesterone Caproate (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM), Double-blinded Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Good Samaritan Hospital
mi
from
San Jose, CA
Click here to add this to my saved trials
Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)
17-alpha-Hydroxyprogesterone Caproate (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM), Double-blinded Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
OConnor Hospital
mi
from
San Jose, CA
Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)
17-alpha-Hydroxyprogesterone Caproate (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM), Double-blinded Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
OConnor Hospital
mi
from
San Jose, CA
Click here to add this to my saved trials
Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)
17-alpha-Hydroxyprogesterone Caproate (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM), Double-blinded Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Presbyterian/St Luke's Hospital
mi
from
Denver, CO
Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)
17-alpha-Hydroxyprogesterone Caproate (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM), Double-blinded Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Presbyterian/St Luke's Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)
17-alpha-Hydroxyprogesterone Caproate (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM), Double-blinded Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Swedish Medical Center
mi
from
Denver, CO
Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)
17-alpha-Hydroxyprogesterone Caproate (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM), Double-blinded Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Swedish Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials